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A path to the future in scleroderma
In October of 2007, a group of true experts in diverse areas
relevant to scleroderma were invited to Florence, Italy for a 2-day
symposium on ‘Controversies in Scleroderma’. As the organizing
committee for this activity, we selected the topics and speakers
and the format of the meeting which focused on brief cutting-edge
presentations followed by intensive group discussions.
This Supplement to Rheumatology seemed inescapably impor-
tant to realize as a summary of the conference and as a
compendium for the student of scleroderma everywhere. Each
author was asked to write a concise treatise on their individual
area of expertise and to follow a uniform format for under-
standability and accessibility.
Full answers are not yet in to critically important questions
in scleroderma but progress is considerable. We work in an era
of excitement, collaboration and anticipation. The biological
platform for considering interventions has never been stronger.
We have several plausible molecular targets and the intellectual
framework via which we can stratify our approach. As our under-
standing of the vascular, immunological and fibrotic features of
disease evolves, new hypotheses will emerge and hopefully be
efficiently and appropriately tested in controlled clinical trials.
However, these trials will not be robust unless there is progress in
the clinical sciences of trial design and outcome measures.
Scleroderma is a remarkably heterogeneous disorder. It is likely
that progress in therapy will be focused on both specific features
of disease and on overarching approaches to the commonalities of
disease pathogenesis that are expressed in all patients. Lung
disease remains the leading cause of death with parenchymal and
vascular pathologies being of near equal importance. This
conference paid particular attention to new knowledge in both
areas that will permit efficient study of well-documented cohorts
of clinically and pathophysiologically similar patients.
There is a lot here but also a lot of work ahead! We have better
science and a sophisticated approach to clinical management and
trial design. Effective treatments seem within reach.
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